Oramed Pharmaceuticals sell Amped
Start price
29.12.21
/
0%
€10.70
Target price
29.12.22
-
Performance (%)
5.37%
End price
30.12.22
€11.28
Summary
This prediction ended on 30.12.22 with a price of €11.28. With a performance of 5.37%, the SELL prediction by Amped for Oramed Pharmaceuticals was trending in the wrong direction This prediction was marked as speculative and is excluded from Amped's performance statistics.Oramed is a pharmaceutical company that focuses on the development of innovative oral delivery solutions for drugs that are traditionally administered through injection. The company is primarily dedicated to the development of an oral insulin capsule that can potentially revolutionize the treatment of diabetes. Their flagship product, ORMD-0801, is currently in Phase III clinical trials in the United States and has received Fast Track designation from the FDA. Oramed is a publicly traded company listed on the Nasdaq under the ticker symbol ORMP.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Oramed Pharmaceuticals | -2.649% | -2.649% | 5.251% |
| iShares Core DAX® | 2.112% | -0.367% | 13.466% |
| iShares Nasdaq 100 | -2.197% | -3.794% | 38.426% |
| iShares Nikkei 225® | -1.555% | -7.320% | 18.451% |
| iShares S&P 500 | -0.472% | -2.078% | 27.488% |
According to Amped what are the pros and cons of Oramed Pharmaceuticals for the foreseeable future?
Pros
Future proof or reliable business model
Cons
Risky Investment
Mainly gamblers invest here
Sustainability is not important
High valuation
Revenue decline/stagnation expected
Growths slower than the competition
Little known brand
Significant cyclical dependencies
Comments by Amped for this prediction
In the thread Oramed Pharmaceuticals diskutieren
Sell Oramed Pharmaceuticals
In the thread Trading Oramed Pharmaceuticals
Die von Amped gewählte maximale Laufzeit wurde überschritten